Turmeric nanoparticle gel put to the test against diabetic foot ulcers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed written informed consent obtained prior to the first study assessment; * Male or female patients aged \>= 20 and \< 80 years; * Diagnosed with diabetes mellitus (type 1 or type 2) with HbA1c \< 12.0% detected during the screening period or within three months prior to randomization; * Ankle-Brachial Index (ABI) of the target limb \>= 0.8 measured during screening or within three months prior to randomization; * The target ulcer must meet all of the following criteria: a. Wagner Ulcer Grading System grade 1 to 3; b. Located at or below the ankle; c. No infection or mild infection (as defined by IWGDF/IDSA criteria); d. Cross-sectional area after debridement between 1 and 25 cm²; e. Present for at least 4 weeks prior to randomization; * For women of childbearing potential, negative pregnancy test and not currently breastfeeding at the screening visit; * Willing and able to attend scheduled visits and comply with study procedures; Exclusion Criteria: * Presence of gangrene, suppuration, or sinus tract that cannot be removed by debridement; * Diagnosis of acute Charcot neuroarthropathy based on clinical and/or radiographic examination; * Undergone revascularization procedures aimed at increasing blood flow to the target limb within 4 weeks prior to randomization; * Poor nutritional status, defined as albumin \< 2.5 g/dL; * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 times the upper limit of normal; * Presence of acute biliary tract diseases such as acute cholecystitis or cholelithiasis; * Serum creatinine \> 2 times the upper limit of normal; * Coagulation abnormalities, recent surgery, or severe trauma; * Diagnosed with cerebral hemorrhage within 4 weeks prior to randomization; * 10\. Received immunosuppressants, chemotherapeutic agents, radiotherapy, or systemic corticosteroids within 4 weeks prior to randomization; * Use of any investigational drug or treatment within 4 weeks prior to randomization; * Known allergy to curcumin or hydrogel; * Pregnant or breastfeeding women; * Psychiatric conditions (e.g., suicidal ideation), current or long-term alcohol or substance abuse, as determined by the patient's medical history, which in the investigator's opinion may compromise compliance; * Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this trial.